{"entity":{"id":"nct07168200","kind":"trial","name":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the","aka":[],"tldr":"A phase 3 trial of Adebrelimab, Cisplatin, Carboplatin in cervical cancer, run by Shanghai Shengdi Pharmaceutical Co., Ltd, now recruiting.","summary":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer is a phase 3 interventional study registered as NCT07168200 by Shanghai Shengdi Pharmaceutical Co., Ltd, with 720 participants planned, started 2025-10-17 and due to reach its primary completion in 2028-04. Interventions recorded: SHR-1316 Injection, Cisplatin Injection, Carboplatin Injection, Paclitaxel Injection, SHR-1316 Placebo Injection. Conditions listed: Advanced Cervical Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07168200","url":"https://clinicaltrials.gov/study/NCT07168200"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cervical","locally-advanced-cervical-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","monoclonal-antibody"],"targets":[],"drugs":["adebrelimab","cisplatin","carboplatin","paclitaxel"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07168200","phase":"3","setting":"A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","started":"2025-10-17","startedType":"actual","enrolled":720,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07168200/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"locally-advanced-cervical-cancer","kind":"cancer","name":"Locally advanced cervical cancer","route":"/cancers/locally-advanced-cervical-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}